Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of hospital-acquired infections
3.2.1.2 Advancements in medical technology and drug development
3.2.1.3 Growing focus on patient safety and quality care
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of patient awareness and diagnostics
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
3.6 Reimbursement scenario
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Pipeline analysis
3.10 Future market trends
3.11 Gap analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Antibacterial drugs
5.3 Antiviral drugs
5.4 Antifungal drugs
5.5 Other drug types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Intravenous (IV)
6.3 Oral
6.4 Topical
6.5 Inhalation
Chapter 7 Market Estimates and Forecast, By Infection Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Surgical site infections
7.3 Bloodstream infections
7.4 Urinary tract infections
7.5 Ventilator-associated pneumonia
7.6 Other hospital infections
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
Chapter 9 Company Profiles
9.1 Abbott
9.2 AbbVie
9.3 Allergan
9.4 Eugia Pharma
9.5 Bayer
9.6 DAIICHI SANKYO COMPANY
9.7 F. Hoffmann-La Roche
9.8 Glenmark Pharmaceuticals
9.9 GSK
9.10 Hikma Pharmaceuticals
9.11 Melinta Therapeutics
9.12 Merck & Co
9.13 Pfizer
9.14 Sanofi
9.15 Viatris
